Merck opens testing plant in latest Korean bioprocessing investment

By Dan Stanton

- Last updated on GMT

Korean CMO Samsung Biologics endorsed Merck's new bioprocessing collaboration centre
Korean CMO Samsung Biologics endorsed Merck's new bioprocessing collaboration centre

Related tags South korea

Germany’s Merck has opened a bioprocessing collaboration centre in Songdo, Incheon - the latest investment supporting the burgeoning Korean biopharma industry.

The firm’s global M Lab Collaboration Centers enable biomanufacturing firms to view and test bioprocessing equipment, and a newly unveiled 1,865m2​ site reflects Korea’s growing biopharma ambitions, the firm says.

“With a rapidly growing biopharmaceutical industry in Korea and demand for novel and cost-effective therapies worldwide, there is a clear need for innovative concepts like our M Lab Collaboration Centers,”​ said Udit Batra, CEO of the firm’s Life Science division.

The facility replaces a smaller site in Seoul and is located in the area of Songdo, Incheon – a ‘smart city’ reclaimed from the sea – which is home to a number of biopharma firms including Celltrion​ and Samsung Biologics​ which are investing heavily in their respective biomanufacturing capacities.

In fact, the CEO of the latter - TH Kim – endorsed Merck’s new facility in a statement, saying it will play an important role in supporting the local biomanufacturing market.

“Merck's decision to invest in Songdo, fast growing as world largest biologics manufacturing hub with 520,000L of plant capacity by 2018, represents a significant milestone in the development of the Songdo Bio Cluster, which will accelerate the future growth of Incheon as well as Korean Biopharmaceutical industry.”

The unveiling complements a four year plan​ recently announced by the South Korean government intended to fuel the growth of the country's bio-health industry through incentives including offering drug companies higher tax benefits.

Merck joins fellow bioprocessing technology firm GE Healthcare, which only last week​ announced it had opened a 2,200m2​ training centre in Songdo at a cost of $7.4m.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us

Products

View more

Webinars